The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.1 - Manufacture of basic pharmaceutical products
235 jobs Number of planned job losses
Announcement Date
4 February 2013
Employment effect (start)
1 March 2013
Foreseen end date
31 December 2013
Description
On 4 February 2013, the US pharmaceutical group Bristol-Myers Squibb announced that 235 workers will be made redundant. The job cuts will mainly affect its commercial workforce.
The US group has to deal with the loss of several key patents and a renegotiation of partnerships with Sanofi and Otsuka to sell pharmaceutical products.
The group closed a plant in France in 2010 with 110 consequent job losses including 85 forced dismissals (see here). In July 2012, the former employees won a lawsuit that was taken to the employment tribunal and BMS has to pay them 1,2 million euro for unfair dismissal procedures.
Eurofound (2013), Bristol-Myers-Squibb (BMS), Internal restructuring in France, factsheet number 74888, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/74888.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
